The strong cash position and positive clinical data de-risk the pipeline significantly. The key catalyst to watch is the APEX Part B 16-week data expected in Q2 2026, which will determine the induction dosing regimen for Phase 3 trials. The stock should trade on clinical data readouts and pipeline expansion announcements rather than quarterly financial results.
APGE drugs
APGE drug pipeline →Price Chart
Executive Summary
Apogee Therapeutics reported Q1 2026 results with a net loss of $74.1M, wider than the $55.3M loss in Q1 2025, driven by increased R&D and G&A spending. The key positive was the strong cash position of $1.3B following a $403M upsized public offering, extending runway into 2029, and positive pipeline updates including APEX Phase 2 Part A 52-week data showing durable maintenance with quarterly or less frequent dosing.
Key Facts
- Cash, cash equivalents, and marketable securities totaled $1.3B as of March 31, 2026, up from $902.9M at year-end 2025
- Completed $403M upsized public equity offering following positive Phase 2 APEX Part A readout
- Net loss widened to $74.1M in Q1 2026 from $55.3M in Q1 2025, driven by higher R&D ($60.8M vs $46.4M) and G&A ($22.0M vs $16.7M) expenses
- APEX Phase 2 Part A 52-week data showed durable maintenance: 75-85% of Week 16 EASI-75 responders maintained response at Week 52 with every 3- or 6-month dosing
- Phase 3 initiation in atopic dermatitis expected in H2 2026; APEX Part B 16-week data expected in Q2 2026
- Positive Phase 1b asthma results reported in January 2026; expansion into asthma and EoE trials planned
- Cash runway extended into 2029, through planned BLA filing for zumilokibart in AD
Financial Impact
Net loss of $74.1M in Q1 2026 vs $55.3M in Q1 2025; cash position strengthened to $1.3B from $902.9M
Risk Factors
- Clinical trial failure or disappointing data in upcoming readouts (APEX Part B, APG279 head-to-head)
- Dilution risk from potential future equity offerings to fund Phase 3 trials and commercialization
- Competitive pressure from existing therapies like DUPIXENT and other IL-13/TSLP targeting programs
- Regulatory risk: BLA filing and approval are not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-215683 |
| Document: apge-20260511.htm | 0001193125-26-215683 |
| Document: 0001193125-26-215683-index-headers.html | 0001193125-26-215683 |
| Document: 0001193125-26-215683-index.html | 0001193125-26-215683 |
| Document: 0001193125-26-215683.txt | 0001193125-26-215683 |
| 8-K Data (Synthetic) | 0001193125-26-215683 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers